IPF Failure Sets Back Biogen’s Diversification Efforts

 
• By Mandy Jackson

The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.

lung illustration
BG00011 was being tested to see if it could improve lung function in IPF. • Source: Shutterstock

More from Clinical Trials

More from R&D